

CCR MANUSCRIPT NOTIFICATION (NOVEMBER 2009)

Laboratory of Immune Cell Biology - Jonathan Ashwell, M.D.

There were no submissions reported this month.

Vaccine Branch - Jay Berzofsky, M.D., Ph.D.

Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, McPherson JM, and **Berzofsky JA**: Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor-beta Monoclonal Antibody. *Clin. Cancer Res.* 15(21): 6560-6569, 2009. (VB)

Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, **Klinman DM**, and **Berzofsky JA**: Using three TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. *J. Clin. Invest.* In press. (VB)

Takaku S, Terabe M, Ambrosino E, Peng J, Lonning S, McPherson J, and **Berzofsky JA**: Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8+ T cells. *Int. J. Cancer.* In press. (VB)

CCR Nanobiology Program - Robert Blumenthal, Ph.D.

Bossart KN, Zhu Z, Middleton D, Klippel J, Cramer G, Bingham J, McEachern, JA, Green D, Hancock TJ, Chan YP, Hickey AC, **Dimitrov DS**, Wang LF, and Broder CC: A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. *PLoS Pathogens.* 5(10): e1000642, 2009. (CCRNP)

Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessel AJ, Tang M, Xu L, Yang Z-Y, Zhang M-Y, Arthos J, Burton D, **Dimitrov DS**, Nabel GJ, Posner M, Sodroski J, Wyatt R, Mascola JR, and Kwo PD: Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. *Science.* In press. (CCRNP)

Xiao X, Chen W, Feng Y, and **Dimitrov DS**: Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. *Viruses.* In press. (CCRNP)

Laboratory of Population Genetics - Kenneth Buetow, Ph.D.

There were no submissions reported this month.

Molecular Discovery Program - R. Andrew Byrd, Ph.D.

Structural Biophysics Laboratory - R. Andrew Byrd, Ph.D.

There were no submissions reported this month.

Molecular Targets Laboratory - James McMahon, Ph.D.

There were no submissions reported this month.

Chemical Biology Laboratory - Joel Schneider, Ph.D.

Liu F, Stephen AG, Waheed AA, **Freed EO**, Fisher RJ, and **Burke Jr TR**: Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists. *Bioorg & Med Chem Lett.* 20: 318-321, 2010. (CBL)

Radiation Oncology Branch - Kevin Camphausen, M.D.

Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, **Brechbiel MW**, Murone C, and Scott AM: Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. *Clin Cancer Res.* 15(21): 6709-6715, 2009. (ROB)

Kamrava M, Bernstein MB, **Camphausen K**, and **Hodge JW**: Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? *Mol Biosyst.* 5(11): 1262-1270, 2009. (ROB)

Zheng J, Zhang D, Przytycki PF, Zielinski R, **Capala J**, and Przytycka TM: SimBoolNet - A Cytoscape Plugin for Dynamic Simulation of Signaling Networks. *Bioinformatics.* In press. (ROB)

Kamrava M, **Gius D**, Casagrande G, and **Kohn E**: Will targeting insulin growth factor help us or hurt us? An oncologist's perspective. *Aging Res Rev.* In press. (ROB)

Molecular Imaging Program - Peter Choyke, M.D.

Alford R, Ogawa M, **Choyke PL**, and Kobayashi H: Molecular probes for the in vivo imaging of cancer. *Mol Biosyst.* 5(11): 1279-1291, 2009. (MIP)

Turkbey B, Thomasson D, Pang Y, Bernardo M, and **Choyke PL**: The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. *Diagn Interv Radiol.* In press. (MIP)

Shah V, Pohida T, Turkbey B, Mani H, **Merino MJ**, Pinto PA, **Choyke PL**, and Bernardo M: A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds. *Rev Sci Instrum.* 80(10): 104301, 2009. (MIP)

Kosaka N, Ogawa M, **Choyke PL**, and Kobayashi H: Clinical implications of near-infrared fluorescence imaging in cancer. *Future Oncol.* 5(9): 1501-1511, 2009. (MIP)

Ogawa M, Regino CA, Seidel J, Green MV, Xi W, Williams M, Kosaka N, **Choyke PL**, and Kobayashi H: Dual-Modality Molecular Imaging Using Antibodies Labeled with Activatable Fluorescence and a Radionuclide for Specific and Quantitative Targeted Cancer Detection. *Bioconjug Chem.* 20(11): 2177-2184, 2009. (MIP)

Laboratory of Cancer Prevention - Nancy Colburn, Ph.D.

There were no submissions reported this month.

Neuro-Oncology Branch - Howard Fine, M.D.

Iwamoto F, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PA, and **Fine HA**: Phase II Trial of Talampanel, a Glutamate Receptor Inhibitor, for Adults with Recurrent Malignant Gliomas. *Cancer.* In press. (NOB)

Medical Oncology Branch - Giuseppe Giaccone, M.D., Ph.D.

Kummar S, Gutierrez ME, Gardner ER, Chen X, **Figg WD**, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Conley BA, **Giaccone G**, **Doroshov JH**, and Murgo AJ: Phase I Trial of 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), A Heat Shock Protein Inhibitor, Administered twice weekly in Patients with Advanced Malignancies. *Eur. J. Cancer.* In press. (MOB)

Zhu W, Zhu D, Madan R, **Gully J**, **Figg WD**, and **Dahut WL**: Treatment of Castration Resistant Prostate Cancer: Updates on Therapeutics Targeting the Androgen Receptor Signaling Pathway. *Am. J. Ther.* In press. (MOB)

Chau C and **Figg WD**: New Tricks from an Old Drug: A Role for Quinacrine in Anti-Cancer Therapy? *Cell Cycle.* In press. (MOB)

Sissung TM, Baum CE, Kirkland CT, Gardner ER, and **Figg WD**: Pharmacogenetics of Membrane Transporters: An Update on Current Approaches. *Mol. Biotechnol.* In press. (MOB)

Sissung TM, English BC, Venzon D, **Figg WD**, and Deeken JF: Clinical Pharmacology and Pharmacogenetics in a Genomics Era: The DMET Platform. *Pharmacogenomics.* In press. (MOB)

Kluetz PG, **Figg WD**, and **Dahut WL**: Angiogenesis Inhibitors in the Treatment of Prostate Cancer. *Expert Opin. Pharmacother.* In press. (MOB)

Chau C and **Figg WD**: Angiogenesis Therapy. DeVita VT and **Rosenberg SA** (Eds). In: *Cancer: Principles and Practice of Oncology 9th Edition.* In press. (MOB)

Piekarz RL, Frye R, **Turner M**, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard J, Geskin L, Reeder C, Joske D, **Figg WD**, Gardner ER, Steinberg SM, **Jaffe E**, **Stetler-Stevenson M**, Lade S, **Fojo AT**, and **Bates SE**: A multi-institutional phase II trial of the HDAC inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. *J. Clin. Oncol.* In press. (MOB)

Laboratory of Metabolism - Frank Gonzalez, Ph.D.

There were no submissions reported this month.

Laboratory of Cell Biology - Michael Gottesman, M.D.

Appella E and Anderson CW: Dynamic interactions of proteins in complex networks. *FEBS J.* 276: 5380, 2009. (LCB)

Hirai T, **Subramaniam S**, and Lanyi JK: Structural snapshots of conformational changes in a seven-helix membrane protein: lessons from bacteriorhodopsin. *Curr. Opin. Struct. Biol.* 19: 433-439, 2009. (LCB)

Kucka M, Kretschmannova K, Murano T, Wu CP, Zemkova H, **Ambudkar SV**, and Stojilkovic SS: Dependence of multidrug resistance protein-mediated cyclic nucleotide efflux on the background sodium conductance. *Mol Pharmacol.* In press. (LCB)

Lund PE, Hunt RC, **Gottesman MM**, and Kimchi-Sarfaty C: Pseudovirions as vehicles for the delivery of siRNA. *Pharm Res.* In press. (LCB)

Sahu G, Wang DF, Chen CB, **Zhurkin VB**, Harrington RE, **Appella E**, **Hager GL**, and Nagaich AK: P53 binding to nucleosomal DNA depends on the rotational positioning of DNA response element. *J. Biol. Chem.* In press. (LCB)

Tang WK, Li D, Esser L, and **Xia D**: Purification, crystallization and preliminary X-ray diffraction analysis of disease-related mutants of p97. *Acta Crystallogr Sect F Struct Biol Cryst Commun.* 65: 1166-1170, 2009. (LCB)

Experimental Transplantation and Immunology Branch - Ronald Gress, M.D.

There were no submissions reported this month.

Laboratory of Receptor Biology and Gene Expression - Gordon Hager, Ph.D.

Nishiyama A, Karpova T, **McNally JG** and Ozato K: Brd4 marks select genes on mitotic chromatin and directs post-mitotic tra. *MBG.* In press. (LRBGE)

Hager GL, **McNally JG**, and **Misteli T**: Transcription dynamics. *Molecular Cell.* 35: 741-753, 2009. (LRBGE)

Stavreva DA, Wiench M, John S, Conway-Campbell BL, McKenna MA, Pooley JR, Johnson TA, Voss TC, Lightman SL, and **Hager GL**: Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. *Nature Cell Biol.* 11: 1093-1102, 2009. (LRBGE)

Sung MH, Salvatore L, De Lorenzi R, Indrawna A, Pasparakis M, **Hager GL**, Bianchi ME, and Agresti A: Sustained oscillations of NF-kappaB produce distinct genome scanning and gene expression profiles. *PLoS One.* 4: e7163, 2009. (LRBGE)

McNally JG and Mazza D: Fractal Geometry in the Nucleus. *EMBO Journal.* In press. (LRBGE)

Pegoraro G, Kubben L, Wickert U, Gohler H, Koffman K, and **Misteli T**: Aging-related chromatin defects via loss of the NURD complex. *Nature Cell Biol.* 10: 1261-1267, 2009. (LRBGE)

Mott BT, Tanega C, Shen M, Maloney DJ, Shinn P, Leister W, Marugan JJ, Inglese J, Austin CP, **Misteli T**, Auld DS, and Thomas CJ: Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). *BMC Letters.* 19: 6700-6705, 2009. (LRBGE)

Laboratory of Human Carcinogenesis - Curtis Harris, M.D.

There were no submissions reported this month.

HIV Drug Resistance Program - Stephen Hughes, Ph.D.

HIV DRP Host Virus Interaction Branch – Stephen Hughes, Ph.D.

Boltz VF, **Maldarelli F**, Martinson N, Morris L, McIntyre JA, Gray G, Hopley MJ, Kimura T, Mayers DL, Robinson P, Mellors JW, Coffin JM, and Palmer SE: Optimization of allele-specific PCR using patient specific HIV consensus sequences for primer design. *J. Virol. Methods*. In press. (HVIB)

Halvas EK, Wiegand A, Boltz VF, **Kearney M**, Nissley D, Wantman M, Hammer S, Palmer S, Vaida F, Coffin JM, and Mellors JW: Low frequency NNRTI-resistant variants contribute to failure of Efavirenz-containing regimens in treatment-experienced patients. *J. Infect. Dis.* In press. (HVIB; PI: **Maldarelli F**)

McMahon D, Jones J., Wiegand A, Gange SJ, **Kearney M**, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, and **Maldarelli F**: Short course Raltegravir intensification does not reduce persistent low level viremia in patients suppressed on combination antiretroviral therapy. *Clin. Infect. Dis.* In press. (HVIB)

Retroviral Replication Laboratory - Stephen Hughes, Ph.D.

Chung S, Rausch JW, and **Le Grice SFJ**: Targeting HIV-1 reverse transcriptase: a coat with many pockets. In: *Innovations in Pharmaceutical Technology*. Vol. 31, pp 48-51, 2009. (RRL)

Laboratory of Comparative Carcinogenesis - Larry Keefer, Ph.D.

There were no submissions reported this month.

Cell and Cancer Biology Branch - Kathleen Kelly, Ph.D.

There were no submissions reported this month.

Urologic Oncology Branch - W. Marston Linehan, M.D.

There were no submissions reported this month.

Laboratory of Cellular Oncology - Douglas Lowy, M.D.

There were no submissions reported this month.

Pediatric Oncology Branch - Crystall Mackall, M.D.

There were no submissions reported this month.

Genetics Branch - Paul Meltzer, M.D., Ph.D.

There were no submissions reported this month.

Lab of Cancer Biology & Genetics - Glenn Merlino, PhD and Stuart Yuspa, MD

There were no submissions reported this month.

Radiation Biology Branch - James Mitchell, Ph.D.

There were no submissions reported this month.

Laboratory of Cell and Developmental Signaling - Debbie Morrison, Ph.D.

There were no submissions reported this month.

Laboratory of Pathology - J. Carl Oberholtzer, M.D., Ph.D.

Arun I, Wulu JA, **Janik JE**, Jasper GA, Yuan CM, Venzon D, and **Stetler-Stevenson M**: Visual inspection versus quantitative flow cytometry to detect aberrant CD2 expression in malignant T cells. Clin. Cytometry. In press. (LP)

Frazier WA, Isenberg JS, Kaur S, and **Roberts DD**: CD47. Nature Signaling Gateway. In press. (LP)

Jiang L, Yuan C, Hubachek J, **Janik JE**, **Wilson W**, **Morris JC**, Jasper GA, and **Stetler-Stevenson M**: Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br. J. Haematol. 145: 173-179, 2009. (LP)

Martiniova L, Lai EW, Thomasson D, Kiesewetter DO, Seidel J, **Merino MJ**, Kvetnansky R, and Pacak K: Animal model of metastatic pheochromocytoma: evaluation by MRI and PET. Endocr. Regul. 43(2): 59-64, 2009. (LP)

Mukherjee S, Richardson AM, Rodriguez-Canales J, Ylaya K, Erickson HS, Player A, Kawasaki ES, **Pinto PA**, **Choyke PL**, **Merino MJ**, Albert PS, Chuaqui RF, and **Emmert-Buck MR**: Identification of EpCAM as a molecular target of prostate cancer stroma. Am. J. Pathol. In press. (LP)

O'Mahony D, **Morris JC**, **Stetler-Stevenson M**, Matthews H, Brown MR, Fleisher T, Pittaluga S, **Raffeld M**, Albert PS, Reitsma D, Kaucic K, Hammershaimb L, **Waldmann TA**, and **Janik JE**: EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin. Cancer Res. 15: 2514-2522, 2009. (LP)

Shao H, Yuan CM, Xi L, **Raffeld M**, **Morris JC**, **Janik JE**, and **Stetler-Stevenson M**: Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma. Am. J. Clin. Pathol. In press. (LP)

Stetler-Stevenson M: Flow cytometric immunophenotyping: emerging as an important diagnostic tool in the evaluation of cytopenic patients. Leuk. Res. 33: 1020-1021, 2009. (LP)

Stetler-Stevenson M and Yuan CM: Myelodysplastic syndromes: the role of flow cytometry in diagnosis and prognosis. Int. J. Lab. Hem. In press. (LP)

Laboratory of Genomic Diversity - Stephen O'Brien, Ph.D.

There were no submissions reported this month.

Lab of Molecular Biology - Ira Pastan, M.D. and Susan Gottesman, Ph.D.

Ding D, Kanaly CW, Bigner DD, Cummings TJ, Herndon II JE, **Pastan I**, Raghavan R, and Sampson JH: Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol. In press. (LMB)

Nagata S and **Pastan I**: Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv. Drug Deliv. Rev. 61: 977-985, 2009. (LMB)

Berger EA and **Pastan I**: Immunotoxin complementation of HAART to deplete persisting HIV infected cells. PLoS Pathog. In press. (LMB)

Cereda V, Poole DJ, Palena C, Das S, Bera TK, Remondo C, **Gulley JL**, Arlen PM, Yokokawa J, **Pastan I**, **Schlom J**, and **Tsang KY**: New gene expressed in prostate (NGEP): a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol. Immunother. In press. (LMB)

Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, and **Pastan I**: A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high anti-tumor activity in mice. J. Immunother. In press. (LMB)

Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, and **Pastan I**: Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by anti-mesothelin monoclonal antibody MORAb-009; implications for cancer therapy. Lung Cancer. In press. (LMB)

Feng Y, Xiao X, Zhu Z, Streaker E, **Ho M**, **Pastan I**, and **Dimitrov DS**: A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by ADCC. Mol. Cancer Ther. In press. (LMB)

Pastan I and **Ho M**: Recombinant immunotoxins for treating cancer. Kontermann R and Dübel S (Eds). In: Antibody Engineering. In press. (LMB)

Xiao X, **Ho M**, Zhu Z, **Pastan I**, and **Dimitrov DS**: Identification and characterization of fully human anti-CD22 monoclonal antibodies. mAbs. In press. (LMB)

Lu C and **Cheng SY**: Thyroid hormone receptors regulate adipogenesis and carcinogenesis via cross-talk signaling with peroxisome proliferator-activated receptors. J Mol Endocrinol. In press. (LMB)

Guigon CJ and **Cheng SY**: Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol. 308(1-2): 63-69, 2009. (LMB)

Kreitman RJ, **Fitzgerald DJ**, and **Pastan I**: Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma. 50 Suppl 1: 32-37, 2009. (LMB)

Liu XF, Bera TK, Liu LJ, and **Pastan I**: A primate-specific POTE-actin fusion protein plays a role in apoptosis. Apoptosis. 14(10): 1237-1244, 2009. (LMB)

Cancer & Developmental Biology Lab. - Alan Perantoni, Ph.D. (Acting Chief)
There were no submissions reported this month.

Laboratory of Molecular Pharmacology - Yves Pommier, M.D., Ph.D.

Dexheimer TS, Gediya LK, Stephen AG, Weidlich I, Antony S, Marchand C, Interthal H, **Nicklaus M**, Fisher RJ, Njar VC, and **Pommier Y**: 4-pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. J Med Chem. 52: 7122-7131, 2009. (LMP)

Lebedeva NA, Rechkunova NI, Agama K, **Pommier Y**, and Lavrik OI: Interaction of DNA topoisomerase 1 with DNA intermediates and proteins of base excision repair. Biochem. 74: 1278-1284, 2009. (LMP)

Surgery Branch - Steven Rosenberg, M.D., Ph.D.

There were no submissions reported this month.

Laboratory of Cellular and Molecular Biology - Larry Samelson, M.D.

O'Connell CB, Loncarek J, **Kalab P**, and Khodjakov A: Relative contributions of chromatin and kinetochores to mitotic spindle assembly. *J. Cell Biol.* 187: 43-51, 2009. (LCMB)

Abu-Arish A, **Kalab P**, Ng-Kamstra J, Weis K, and Fradin C: Spatial distribution and mobility of the Ran GTPase in live interphase cells. *Biophys. J.* 97: 2164-2178, 2009. (LCMB)

Laboratory of Tumor Immunology and Biology - Jeffrey Schlom, Ph.D.

Fernando RI, Litzinger M, Trono P, Hamilton DH, **Schlom J**, and **Palena C**: The T-box transcription factor Brachyury promotes epithelial-to-mesenchymal transition in human tumor cells. *J Clin Invest.* In press. (LTIB)

Arlen PM and **Gulley JL**: Current perspectives in prostate cancer vaccines. *Anti-Cancer Agents in Medicinal Chemistry.* 9: 1052-1057, 2009. (LTIB)

Experimental Immunology Branch - Alfred Singer, M.D.

There were no submissions reported this month.

Gene Regulation and Chromosome Biology Lab - Jeffrey Strathern, Ph.D.

There were no submissions reported this month.

Laboratory of Experimental Carcinogenesis - Snorri Thorgeirsson, M.D., Ph.D.

There were no submissions reported this month.

Cancer and Inflammation Program - Giorgio Trinchieri, M.D.

Laboratory of Molecular Immunoregulation - Joost Oppenheim, M.D.

There were no submissions reported this month.

Laboratory of Experimental Immunology - Giorgio Trinchieri, M.D.

Averdam A, Petersen B, Rosner C, Neff J, Roos C, Eberle M, Aujard F, Munch C, Schempp W, **Carrington M**, Shiina T, Inoko H, Knaust F, Coggill P, Sehra H, Beck S, Abi-Rached L, Reinhardt R, and Walter L: A novel system of polymorphic and diverse NK cell receptors in primates. *PLoS Genet.* 5(10): e1000688, 2009. (LEI)

Mazzucchelli RI, Warming S, Lawrence SM, Ishii M, Abshari M, Washington AV, Feigenbaum L, Warner AC, Sims DJ, Li WQ, Hixon JA, Gray DH, Rich BE, Morrow M, Anver MR, Cherry J, Naf D, Sternberg LR, **McVicar DW**, Farr AG, Germain RN, Rogers K, Jenkins NA, Copeland NG, and **Durum SK**: Visualization and identification of IL-7 producing cells in reporter mice. *PLoS One.* 4(11): e7637, 2009. (LEI)

Shanker A, Brooks AD, Jacobsen KM, Wine JW, **Wiltrout RH**, Yagita H, and **Sayers TJ**: Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. *Cancer Res.* 69(16): 6615-6623, 2009. (LEI)

Dermatology Branch - Mark Udey, M.D., Ph.D.

Wang Y, DiGiovanna JJ, Stern JB, Hornyak TJ, **Raffeld M**, Khan SG, Oh K-S, Hollander MC, **Dennis PA**, and **Kraemer KH**: Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. *Proc Natl. Acad. Sci. USA.* 106: 6279-6284, 2009. (DB)

Christen-Zaech S, Imoto K, Khan SG, Oh K-S, Tamura D, DiGiovanna JJ, Boyle J, Patronas NJ, Schiffmann R, **Kraemer KH**, and Paller AS: Unexpected occurrence of xeroderma pigmentosum in an uncle and nephew. *Arch Dermatol* In press. (DB)

Subramanian M, Gonzalez RW, Patil H, Ueda T, Lim J-H, **Kraemer KH**, **Bustin M** and Bergel M: High mobility group nucleosomal protein 2 is involved in global genome repair. *FEBS Journal.* In press. (DB)

Ueda T, Compe E, Catez P, **Kraemer KH** and Egly JM: Both XPD alleles contribute to the phenotype of compound heterozygote xeroderma pigmentosum patients. *J Exp. Med.* In press. (DB)

Wang Y, Tan XH, DiGiovanna JJ, Richard Lee CC, Stern JB, **Raffeld M**, **Jaffe ES**, and **Kraemer KH**: Genetic diversity in melanoma metastases from a patient with xeroderma pigmentosum. *J. Investigative Dermatol.* In press. (DB)

Moslehi R, Signore C, Tamura D, Mills JL, DiGiovanna JJ, Tucker MA, Troendle J, Ueda T, Boyle J, Khan SG, Oh K-S, Goldstein AM and **Kraemer KH**: Adverse Effects of Trichothiodystrophy DNA Repair and Transcription Gene Disorder on Human Fetal Development. Clinical Genetics. In press. (DB)

Khan SG, Yamanegi K, Zheng Z-M, Boyle J, Imoto K, Oh K-S, Baker CC, Gozukara E, Metin A and **Kraemer KH**: XPC branch-point sequence mutations disrupt U2 snRNP binding resulting in abnormal pre-mRNA splicing in xeroderma pigmentosum patients. Human Mutation. In press. (DB)

Mouse Cancer Genetics Program - Terry Van Dyke, Ph.D.

There were no submissions reported this month.

Mammary Biology & Tumorigenesis Lab - Barbara Vonderhaar, Ph.D.

There were no submissions reported this month.

Metabolism Branch - Thomas Waldmann, M.D.

There were no submissions reported this month.

Laboratory of Protein Dynamics & Signaling - Allan Weissman, M.D.

There were no submissions reported this month.

Macromolecular Crystallography Laboratory - Alexander Wlodawer, Ph.D.

There were no submissions reported this month.

Laboratory of Biochemistry and Molecular Biology - Carl Wu, Ph.D.

There were no submissions reported this month.

HIV and AIDS Malignancy Branch - Robert Yarchoan, M.D.

There were no submissions reported this month.

Basic Research Laboratory

There were no submissions reported this month.

Emeritus Scientists

There were no submissions reported this month.

SAIC Frederick

AIDS and Cancer Virus Program - Jeffrey Lifson, M.D.

There were no submissions reported this month.